Sánchez, RicardoAyala Díaz, Rosa MaríaMartínez López, Joaquín2023-06-172023-06-172019-06-101422-006710.3390/ijms20112832https://hdl.handle.net/20.500.14352/12572Ultra-deep next-generation sequencing has emerged in recent years as an important diagnostic tool for the detection and follow-up of tumor burden in most of the known hematopoietic malignancies. Meticulous and high-throughput methods for the lowest possible quantified disease are needed to address the deficiencies of more classical techniques. Precision-based approaches will allow us to correctly stratify each patient based on the minimal residual disease (MRD) after a treatment cycle. In this review, we consider the most prominent ways to approach next-generation sequencing methodologies to follow-up MRD in hematological neoplasms.engAtribución 3.0 Españajournal articlehttps://doi.org/10.3390/ijms20112832https://www.mdpi.com/1422-0067/20/11/2832open accessminimal residual diseasenext-generation sequencingclonal evolutionhematological neoplasmshigh-throughput sequencingOncología3201.01 Oncología